Gene Immunotherapy for Non-Small Cell Lung Cancer
Historically, limited results have been observed with immunity in non-small cell lung cancer (NSCLC). In the last 5 years, however, several immune-stimulating products have demonstrated enhancement of tumor antigen recognition through activation of dendritic cell-involved processes. Moreover, clinical benefit has been demonstrated in subsets of patients, justifying ongoing phase III investigation. Results of key gene immunotherapies being tested in NSCLC are reviewed. Preliminary results in advanced NSCLC suggest evidence of well-tolerated immune activation with suggested evidence of clinical benefit with respect to survival and response.
- 上一篇
Detection of MetastaticTumor Cells in Blood by Reverse Transcriptase-Polymerase Chain Reaction
In oncology, the correct assessment of tumor stage is crucia...
- 下一篇
Suppression Subtractive Hybridization for Identification and Functional Analysis of Tumor Suppressor
Alterations leading to inactivation of tumor suppressor gene...